user

October 8, 2021

POP BIO awarded $599,981 Phase 1 SBIR Award to Develop Thermostable COVID-19 Vaccine

BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the microbe responsible for the coronavirus disease 2019 (COVID-19), through the development of a thermostable recombinant nanoparticle vaccine.
February 23, 2021

COVID-19 vaccine developed by UB startup approved for human trials

EuCorVac-19, a next-generation particle-based COVID-19 vaccine incorporating POP BIO's SNAP technology has gained regulatory approval for Phase I/II studies
January 16, 2021

EuCorVac-19 gains regulatory approval for Phase I / II clinical studies

SNAP-based EuBiologics EuCorVac-19 gains regulatory approval for Phase I/II trials in Korea EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a […]
July 16, 2020

POP BIO announces $3M equity investment and JV with Eubiologics for the RSV vaccine development

POP BIO announces $3M investment and JV formation with Eubiologics for the development of an RSV vaccine POP Biotechnologies, Inc. (POP BIO), a preclinical stage biotechnology […]
July 16, 2020

POP BIO awarded $599,897 NIH contract for HIV vaccine development with Scripps Research

POP Biotechnologies awarded $599,897 NIH contract for HIV vaccine development in collaboration with Scripps Research BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,897, […]
April 6, 2020

POP Biotechnologies awarded $399,917 NIH-NCI Phase I STTR in collaboration with Roswell Park

POP Biotechnologies awarded $399,917 NIH-NCI Phase I STTR in collaboration with Roswell Park BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $399,917 Phase I […]